Evidence map›Paper›PMID 34967237›Full record

ArticleMedical decision making : an international journal of the Society for Medical Decision Making2022

An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial.

Mathyn Vervaart, Mark Strong, Karl P Claxton, Nicky J Welton, Torbjørn Wisløff, Eline Aas

Erratum issuedAbstract read
In one paragraph

Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. General-Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations.Medical decision making : an international journal of the Society for Medical Decision Making · 2023
    Trial
  2. A Pragmatic Bayesian Adaptive Trial Design Based on the Value of Information: The Value-Driven Adaptive Design.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article
  3. Article
  4. Methods to Quantify the Importance of Parameters for Model Updating and Distributional Adaptation.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Article
  5. Calculating the Expected Net Benefit of Sampling for Survival Data: A Tutorial and Case Study.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Mathyn VervaartDepartment of Health Management and Health Economics, University of Oslo, Oslo, Norway.ORCID 0000-0003-2678-0132
Mark StrongSchool of Health and Related Research, University of Sheffield, Sheffield, UK.ORCID 0000-0003-1486-8233
Karl P ClaxtonCentre for Health Economics, University of York, York, UK.
Nicky J WeltonPopulation Health Sciences, University of Bristol, Bristol, UK.
Torbjørn WisløffDepartment of Community Medicine, UiT The Arctic University of Norway, Oslo, Norway.ORCID 0000-0002-7539-082X
Eline AasDepartment of Health Management and Health Economics, University of Oslo, Oslo, Norway.

Funding

Medical Research Council G0601721Medical Research Council G0802413Medical Research Council MR/K025643/1
6 · The paper itself

Abstract

backgroundDecisions about new health technologies are increasingly being made while trials are still in an early stage, which may result in substantial uncertainty around key decision drivers such as estimates of life expectancy and time to disease progression. Additional data collection can reduce uncertainty, and its value can be quantified by computing the expected value of sample information (EVSI), which has typically been described in the context of designing a future trial. In this article, we develop new methods for computing the EVSI of extending an existing trial's follow-up, first for an assumed survival model and then extending to capture uncertainty about the true survival model.

methodsWe developed a nested Markov Chain Monte Carlo procedure and a nonparametric regression-based method. We compared the methods by computing single-model and model-averaged EVSI for collecting additional follow-up data in 2 synthetic case studies.

resultsThere was good agreement between the 2 methods. The regression-based method was fast and straightforward to implement, and scales easily to include any number of candidate survival models in the model uncertainty case. The nested Monte Carlo procedure, on the other hand, was extremely computationally demanding when we included model uncertainty.

conclusionsWe present a straightforward regression-based method for computing the EVSI of extending an existing trial's follow-up, both where a single known survival model is assumed and where we are uncertain about the true survival model. EVSI for ongoing trials can help decision makers determine whether early patient access to a new technology can be justified on the basis of the current evidence or whether more mature evidence is needed. HIGHLIGHTS: Decisions about new health technologies are increasingly being made while trials are still in an early stage, which may result in substantial uncertainty around key decision drivers such as estimates of life-expectancy and time to disease progression. Additional data collection can reduce uncertainty, and its value can be quantified by computing the expected value of sample information (EVSI), which has typically been described in the context of designing a future trial.In this article, we have developed new methods for computing the EVSI of extending a trial's follow-up, both where a single known survival model is assumed and where we are uncertain about the true survival model. We extend a previously described nonparametric regression-based method for computing EVSI, which we demonstrate in synthetic case studies is fast, straightforward to implement, and scales easily to include any number of candidate survival models in the EVSI calculations.The EVSI methods that we present in this article can quantify the need for collecting additional follow-up data before making an adoption decision given any decision-making context.

Indexed as

Monte Carlo MethodCost-Benefit AnalysisDisease ProgressionHumansMarkov ChainsRegression AnalysisUncertaintybayesian decision theorycomputational methodseconomic evaluation modelexpected value of sample informationgeneralized additive modelmodel averagingMonte Carlo methodsnonparametric regressionsurvival data

Identifiers

PMID34967237
PMCPMC9189722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.